论文部分内容阅读
目的研究2型糖尿病患者外周血CD62p水平的变化以及服用阿司匹林后对CD62p的影响。方法采用流式细胞仪分别检测32名健康人(NC组),33例2型糖尿病患者(T2DM组)及35例服用阿司匹林(100mg)2个月2型糖尿病患者(Asp组)的血浆血小板活化标志物(CD62p)水平。结果 (1)NC组与T2DM组的血浆血小板活化标志物CD62p水平相比有显著性差异(P<0.01);(2)Asp组与NC组相比血浆血小板活化标志物CD62p水平相比无显著性差异(P>0.05);(3)T2DM组Asp组相比血小板活化标志物CD62p水平相比有显著性差异(P<0.01)。结论 2型糖尿病患者血小板因子CD62p异常升高。而阿司匹林可以明显抑制2型糖尿病患者血小板活性。血小板因子CD62p的检测可以作为2型糖尿病患者使用阿司匹林治疗的一个临床指标。
Objective To study the changes of CD62p in peripheral blood and the effect of aspirin on CD62p in type 2 diabetic patients. Methods Flow cytometry was used to detect plasma platelet activation in 32 healthy subjects (NC group), 33 T2DM patients and 35 aspirin (100 mg) 2 months diabetic patients (Asp group) Marker (CD62p) levels. Results (1) There was a significant difference in the level of CD62p between NC group and T2DM group (P <0.01). (2) There was no significant difference in plasma platelet activation marker CD62p between NC group and Asp group (P> 0.05). (3) Compared with CD62p, the level of platelet activation marker in Asp group was significantly higher than that in T2DM group (P <0.01). Conclusion The platelet factor CD62p is abnormally elevated in type 2 diabetic patients. Aspirin can significantly inhibit platelet activity in patients with type 2 diabetes. The detection of platelet factor CD62p can be used as a clinical indicator of aspirin therapy in patients with type 2 diabetes.